5-amino-1MQ FAQ: common questions answered
An experimental NNMT blocker with animal findings, no human dosing trials and uncertain risks.
Also called: 5-Amino-1MQ, 5-amino-1-methylquinolinium, 5A1MQ, 5-AMQ, 5A-1MQ, 5-amino-1-methylquinolinium iodide, 5-amino-1-methylquinolinium chloride.
NNMT inhibitors · Small-molecule nicotinamide N-methyltransferase inhibitor · Evidence: Animal studies only.
- Is 5-amino-1MQ FDA-approved? No FDA-approved product or label found. January 20, 2026 warning letter names 503B ineligibility; no compound-specific PCAC vote was found.
- How do people take it? By mouth, twice daily; 50 mg total per day. About 1 month. Source: reported by users, not an established dose.
- What's the difference between 5-amino-1MQ and Tirzepatide? 5-amino-1MQ: an experimental NNMT blocker with animal findings, no human dosing trials and uncertain risks. Tirzepatide: a weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects. Why people pair them: users add it for energy or to overcome a weight-loss stall.
- Can I take it with Tirzepatide? Users add it for energy or to overcome a weight-loss stall. No human combination trial was found; benefits cannot be separated from diet or other drugs. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Class-rule inference for an unapproved pharmacological molecule. It is not named; no compound-specific WADA ruling was found.
- How long does a mixed vial last? Community advice says refrigerate and protect from light. Potency, sterility and a safe use-by date after mixing are unknown.
Related to 5-amino-1MQ
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- NAD+ and precursors: NAD+ helps cells use energy; wellness injection benefits remain unproven.
- MOTS-c: A peptide the body makes; injection benefits and safety remain unproven.
- Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- GenoGenix LLC - 718739 - 01/20/2026, FDA · FDA · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
- Australian Register of Therapeutic Goods (ARTG), Therapeutic Goods Administration · TGA
- Drug Product Database: Access the database, Health Canada · Health Canada
- Poisoning, MedlinePlus / US National Library of Medicine
- Rhabdomyolysis, MedlinePlus / US National Library of Medicine
- Clinical Pharmacology & Toxicology Pearl of the Week ~ Unauthorized Injectable Peptides ~, University of Calgary Clinical Pharmacology & Toxicology · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.